Advances in hidradenitis suppurativa
Transcript: BE HEARD I and II
Georgios Nikolakis
Interview recorded Sep 2024, EADV 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
We found very interesting that we have maybe over time a slight increase in response, so giving long term, this biologic does seem to also have a long-term effect, and at the same time, we didn't have any huge safety concerns apart from what we already know from psoriasis, which is the candidiasis. But other than that, there weren't, in my opinion, safety concerns that would make a concern also a long-term treatment for these patients, especially patients which are already having, they're in irreversible stage with multiple tunnels. They also, many of them are not very keen to have yet another surgery. It would be a way to maybe stabilise the disease in an effective manner.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.